# Xenikos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xenikos-b-v

- Industry: Biotechnology
- Headquarters: Nijmegen, Netherlands
- Website: www.xenikos.com
- Total disclosed funding: $35M
- Latest round: Series B (May 15, 2018)
- Investors on record: 4

## About

Xenikos B.V., based in the Netherlands, specializes in innovative immunotherapy solutions for T-cell mediated diseases, focusing on their therapeutic product, T-Guard™, which aims to reset the immune system in critical medical conditions.Xenikos B.V. was founded in 2009 and is headquartered in Nijmegen, Netherlands. The company specializes in immunotherapy solutions, particularly its flagship product, T-Guard™, designed to treat T-cell mediated diseases. The company's CEO and founder is Ypke van Oosterhout, who has a history in the biotechnology sector. Xenikos has undergone a successful funding journey, with the most recent round being a VENTURE DEBT of EUR 40.00 mn, led by Veloxis Pharmaceuticals A/S on December 19, 2022. To date, the company has raised a total of EUR 30.00 mn across 5 deals.Xenikos B.V. specializes in immunotherapy solutions, primarily focusing on its flagship product, T-Guard™, a combination of two toxin-loaded anti-T-cell antibodies designed to reset the immune system in T-cell mediated diseases. T-Guard™ addresses critical medical conditions such as grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) that can occur following allogeneic hematopoietic stem cell transplants. This therapeutic approach seeks to provide a novel treatment avenue for patients with limited options due to the refractory nature of their conditions. Ongoing research is exploring the potential of T-Guard™ for additional clinical indications across various markets, including Europe and North America.Xenikos B.V.'s revenue structure centers around the clinical and therapeutic applications of its product, T-Guard™, particularly in the context of clinical studies and future commercialization. The company engages primarily with healthcare institutions and recruits patients for clinical trials, facilitating the development and testing of its therapeutics. Interactions usually occur through direct engagement with hospitals and clinical research organizations rather than traditional retail channels. As T-Guard™ advances, potential pricing structures will align with typical pharmaceutical models, including negotiating reimbursement agreements and establishing partnerships with healthcare providers to ensure access to the treatment for eligible patients.Xenikos B.V. plans to leverage its recent funding to further develop T-Guard™ and explore its applications in additional clinical indications. The company aims to expand its presence in both European and North American markets to enhance access to its innovative therapies. Following the recent grant funding in December 2022 from the European Innovation Council, the company is focused on advancing their product pipeline while ensuring a robust clinical study framework to support its upcoming launches.

## Funding rounds

- Series B, May 15, 2018, $30M — RA Capital Management, Medicxi
- Series A, Jun 19, 2012, $4.5M — Oost NL, Stichting Sanquin Bloedvoorziening

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A
- Stichting Sanquin Bloedvoorziening — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B